• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences.中国肝细胞癌的管理：求同存异
Clin Mol Hepatol. 2023 Apr;29(2):342-344. doi: 10.3350/cmh.2023.0106. Epub 2023 Mar 16.
2
The clinical management of hepatocellular carcinoma in China: Progress and challenges.中国肝细胞癌的临床管理：进展与挑战。
Clin Mol Hepatol. 2023 Apr;29(2):339-341. doi: 10.3350/cmh.2023.0077. Epub 2023 Mar 16.
3
Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.原发性肝癌的转化治疗和维持治疗。
Biosci Trends. 2021 Jul 6;15(3):155-160. doi: 10.5582/bst.2021.01091. Epub 2021 May 27.
4
[Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)].《中国原发性肝癌诊疗规范（2019年版）》
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):112-128. doi: 10.3760/cma.j.issn.1007-3418.2020.02.004.
5
Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China.中国肝细胞癌外科治疗的变化与挑战。
Biosci Trends. 2021 Jul 6;15(3):142-147. doi: 10.5582/bst.2021.01083. Epub 2021 Mar 14.
6
Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection.中国肝细胞癌的治疗策略：射频消融与肝切除术对比
Jpn J Clin Oncol. 2016 Dec;46(12):1075-1080. doi: 10.1093/jjco/hyw134. Epub 2016 Sep 27.
7
[Early hepatocellular carcinoma].[早期肝细胞癌]
Nihon Rinsho. 2001 Oct;59 Suppl 6:413-6.
8
[Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].[肝细胞癌靶向治疗与免疫治疗的临床进展]
Zhonghua Gan Zang Bing Za Zhi. 2019 Nov 20;27(11):834-837. doi: 10.3760/cma.j.issn.1007-3418.2019.11.005.
9
Advances in Hepatocellular Carcinoma.肝细胞癌的进展
Clin Liver Dis. 2020 Nov;24(4):xiii-xiv. doi: 10.1016/j.cld.2020.08.014.
10
Hepatocellular carcinoma in the era of immunotherapy.免疫治疗时代的肝细胞癌
Curr Probl Cancer. 2018 Jan-Feb;42(1):40-48. doi: 10.1016/j.currproblcancer.2017.10.007. Epub 2017 Nov 15.

引用本文的文献

1
SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming.SNRPB/CCNB1轴通过增强脂质代谢重编程促进肝细胞癌进展和顺铂耐药。
J Exp Clin Cancer Res. 2025 Jul 18;44(1):211. doi: 10.1186/s13046-025-03463-y.
2
Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma.分子诊断与肝细胞癌个性化治疗的新作用
ILIVER. 2024 Feb 9;3(1):100083. doi: 10.1016/j.iliver.2024.100083. eCollection 2024 Mar.
3
METTL1-driven nucleotide metabolism reprograms the immune microenvironment in hepatocellular carcinoma: a multi-omics approach for prognostic biomarker discovery.METTL1驱动的核苷酸代谢重编程肝细胞癌的免疫微环境：一种用于发现预后生物标志物的多组学方法
Front Immunol. 2025 Apr 22;16:1582203. doi: 10.3389/fimmu.2025.1582203. eCollection 2025.
4
α-Fetoprotein model versus Milan criteria in predicting outcomes after hepatic resection for hepatocellular carcinoma: multicentre study.甲胎蛋白模型与米兰标准在预测肝细胞癌肝切除术后结局中的比较：多中心研究
BJS Open. 2025 Mar 4;9(2). doi: 10.1093/bjsopen/zraf041.
5
Integrated Bioinformatic Analysis Reveals the Oncogenic, Survival, and Prognostic Characteristics of TPX2 in Hepatocellular Carcinoma.综合生物信息学分析揭示了TPX2在肝细胞癌中的致癌、生存及预后特征。
Biochem Genet. 2024 Jun 4. doi: 10.1007/s10528-024-10840-3.
6
Apolipoprotein H-based prognostic risk correlates with liver lipid metabolism disorder in patients with HBV-related hepatocellular carcinoma.基于载脂蛋白H的预后风险与乙肝相关肝细胞癌患者的肝脏脂质代谢紊乱相关。
Heliyon. 2024 May 17;10(10):e31412. doi: 10.1016/j.heliyon.2024.e31412. eCollection 2024 May 30.
7
Cell-Membrane-Coated Metal-Organic Framework Nanocarrier Combining Chemodynamic Therapy for the Inhibition of Hepatocellular Carcinoma Proliferation.细胞膜包覆的金属有机框架纳米载体联合化学动力疗法抑制肝癌细胞增殖
Pharmaceutics. 2024 May 5;16(5):619. doi: 10.3390/pharmaceutics16050619.

本文引用的文献

1
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.肝细胞癌的临床实践指南和实际实践：中国视角。
Clin Mol Hepatol. 2023 Apr;29(2):206-216. doi: 10.3350/cmh.2022.0402. Epub 2022 Dec 22.
2
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook.肝细胞癌的整体化管理：肝病学家的综合诊疗手册。
Liver Int. 2022 Dec;42(12):2607-2619. doi: 10.1111/liv.15432. Epub 2022 Oct 11.
3
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.aMAP 风险评分可预测慢性肝炎患者发生肝细胞癌的风险。
J Hepatol. 2020 Dec;73(6):1368-1378. doi: 10.1016/j.jhep.2020.07.025. Epub 2020 Jul 21.
4
Real-world role of performance status in surgical resection for hepatocellular carcinoma: A multicenter study.真实世界中体能状态在肝癌手术切除中的作用：一项多中心研究。
Eur J Surg Oncol. 2019 Dec;45(12):2360-2368. doi: 10.1016/j.ejso.2019.09.009. Epub 2019 Sep 12.
5
Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach.肝细胞癌的治疗策略 ⁇ 多学科方法。
Int J Mol Sci. 2019 Mar 22;20(6):1465. doi: 10.3390/ijms20061465.
6
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).《中国原发性肝癌诊疗规范（2017年版）》
Liver Cancer. 2018 Sep;7(3):235-260. doi: 10.1159/000488035. Epub 2018 Jun 14.
7
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.晚期肝细胞癌患者需要个性化管理：来自临床实践的教训。
Hepatology. 2018 May;67(5):1784-1796. doi: 10.1002/hep.29668. Epub 2018 Apr 6.
8
Comparison of Patterns and Outcomes of Liver Resection for Hepatocellular Carcinoma: East vs West.肝细胞癌肝切除的模式与结果比较：东方与西方
Clin Gastroenterol Hepatol. 2017 Dec;15(12):1972-1974. doi: 10.1016/j.cgh.2017.06.025. Epub 2017 Jun 17.
9
Controversies and evidence of hepatic resection for hepatocellular carcinoma.肝细胞癌肝切除的争议与证据
BBA Clin. 2016 Oct 11;6:125-130. doi: 10.1016/j.bbacli.2016.10.001. eCollection 2016 Dec.
10
Challenge of China's rural health.中国农村卫生面临的挑战。
BMJ. 2016 Apr 12;353:i2003. doi: 10.1136/bmj.i2003.

Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences.

作者信息

Yang Tian, Wang Ming-Da, Xu Xin-Fei, Li Chao, Wu Han, Shen Feng

机构信息

Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China.

出版信息

Clin Mol Hepatol. 2023 Apr;29(2):342-344. doi: 10.3350/cmh.2023.0106. Epub 2023 Mar 16.

DOI:10.3350/cmh.2023.0106
PMID:36924123
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10121302/
Abstract
摘要